Moderna, Inc.

Moderna, Inc. (NASDAQ: MRNA) is a biotechnology company specializing in the development of a new class of medicines based on messenger ribonucleic acid (mRNA) technology. The company focuses on creating therapies and vaccines for infectious diseases, immuno-oncology, rare diseases, and autoimmune conditions, both independently and in collaboration with strategic partners. mRNA medicines work by instructing the body's cells to produce proteins—whether intracellular, membrane-bound, or secreted—that offer therapeutic or preventive benefits, addressing a wide range of medical conditions.

Positive Growth Prospects

• Strong Revenue and Cost Efficiency: Moderna achieved $1.9 billion in total revenues, driven by strong U.S. sales of its COVID-19 vaccine, Spikevax®. The company also improved cost efficiency, reducing the cost of sales as a percentage of product sales to 28%, a significant improvement over the previous year.
• Advances in R&D and Product Approvals: Moderna progressed in its pipeline with pivotal Phase 3 trials for its norovirus and flu vaccines. Positive Phase 3 data for its COVID-19 and RSV vaccines supports upcoming filings for regulatory approval later in 2024.
• Leadership and Strategic Growth: Moderna expanded its Executive Committee with key leadership promotions, strengthening its focus on long-term growth. The acquisition of its Norwood, Massachusetts campus and new partnerships enhance its operational and market position.
• Public Health and Market Leadership: Moderna's global vaccination efforts, including educational campaigns and collaborations, bolster its leadership in respiratory vaccines. The partnership with Coursera on mRNA education also highlights its commitment to public health.

Growth Challenges

• Underperformance of RSV Vaccine: Sales of Moderna's RSV vaccine were significantly below expectations at $10 million, mainly due to late approval and limited customer orders during the contracting season.
• Decline in International Sales: International sales of Spikevax® dropped, largely due to the fulfillment of deferred orders in 2023, signaling potential challenges in sustaining global demand.
• Cash Decrease and Increased Expenditures: Moderna’s cash position decreased to $9.2 billion due to high R&D expenses and the $0.4 billion Norwood campus purchase, indicating potential liquidity challenges.
• Risks in Pipeline and Delays: Moderna faces potential delays in regulatory approvals for key vaccine candidates, especially the flu/COVID combination vaccine, which could affect its market timeline and revenue.
• High R&D and Administrative Costs: Despite cost reductions in administrative expenses, R&D spending remains high at $1.1 billion, which, along with inventory write-downs, poses ongoing financial challenges for the company.

Technical Observation (on the daily chart):

The stock is currently in a sustained downtrend, as seen from the overall decline in the price since mid-year. However, recent price action suggests consolidation, with the price stabilizing near the $41-$45 range. This could indicate a potential base forming. The 21-day moving average (yellow) is at $41.66, and the 50-day moving average (blue) is at $49.83. The stock is trading below both moving averages, which is a bearish signal. However, the narrowing gap between the 21-day and 50-day moving averages could be a sign of reduced downward momentum.

The RSI is at 44.90, which is below the neutral level of 50 but not yet in the oversold territory (<30). This suggests the stock is neither heavily oversold nor showing strong bullish momentum. The 50-day moving average ($49.83) and the psychological level at $50 are immediate hurdles for a bullish reversal. The recent low near $41 acts as a key support level. A break below this level could result in further downside. The stock is showing signs of stabilization but lacks confirmation of a trend reversal.

Moderna's third-quarter 2024 report highlights strong revenue growth, driven by robust U.S. sales of its COVID-19 vaccine, and notable advancements in its research pipeline, including Phase 3 trials for its norovirus and flu vaccines. The company also demonstrated cost efficiency, reducing sales costs and expanding its leadership team. However, it faced challenges with underwhelming RSV vaccine sales and declining international revenues. Additionally, despite a solid cash position, ongoing high R&D expenses and the purchase of a strategic campus contributed to a decrease in cash reserves, raising concerns about liquidity. Delays in regulatory approvals for key products also pose risks to its future performance.

As per the above-mentioned price action, recent key business and financial updates, momentum in the stock over the last month, and technical indicators analysis, a ‘Watch’ rating has been given to Moderna, Inc. (NASDAQ: MRNA) at the current market price of USD 43.18 as of December 10,2024 at 07:20 AM PST. 

Individuals can evaluate the stock based on the support and resistance levels provided in the report in case of keen interest taking into consideration the risk-reward scenario. 

Markets are trading in a highly volatile zone currently due to certain macro-economic issues and prevailing geopolitical tensions. Therefore, it is prudent to follow a cautious approach while investing.

Related Risk: This report may be looked at from a high-risk perspective and a recommendation is provided for a short duration. This report is solely based on technical parameters, and the fundamental performance of the stocks has not been considered in the decision-making process. Other factors which could impact the stock prices include market risks, regulatory risks, interest rates risks, currency risks, social and political instability risks etc. 

Note 1: Past performance is not a reliable indicator of future performance.

Note 2: The reference date for all price data, currency, technical indicators, support, and resistance level is December 10,2024 at 07:20 AM PST. The reference data in this report has been partly sourced from REFINITIV.

Note 3: Investment decisions should be made depending on an individual's appetite for upside potential, risks, holding duration, and any previous holdings. An 'Exit' from the stock can be considered if the Target Price mentioned as per the Valuation and or the technical levels provided has been achieved and is subject to the factors discussed above.

Note 4: Target Price refers to a price level that the stock is expected to reach as per the relative valuation method and or technical analysis taking into consideration both short-term and long-term scenarios.

Note 5: ‘Kalkine reports are prepared based on the stock prices captured either from the New York Stock Exchange (NYSE), NASDAQ Capital Markets (NASDAQ), and or REFINITIV. Typically, all sources (NYSE, NASDAQ, or REFINITIV) may reflect stock prices with a delay which could be a lag of 15-20 minutes. There can be no assurance that future results or events will be consistent with the information provided in the report. The information is subject to change without any prior notice.